AGM 100
One Device Multiple Parameters
Improve diagnostic and treatment decisions with fast, accurate, and non-invasive assessments of cardiorespiratory status using the AGM100
What is AGM100?
The AGM100, a non-invasive pulmonary gas exchange analyzer, offers a significant advancement in the early detection and management of respiratory conditions. By providing accurate and instantaneous measurements of blood and alveolar oxygen levels, the AGM100 empowers healthcare providers to identify potential respiratory issues at an earlier stage, leading to more timely interventions and improved patient outcomes.
Key Benefits Of AGM100
Catch What Pulse Oximetry Misses, Before It Becomes Critical.
Non-Invasive Pulmonary Gas Exchange Analysis
The AGM100 delivers real-time measurements of critical respiratory parameters, gPaO₂, PAO₂, EtCO₂, Oxygen Deficit (A-a Gradient Surrogate), SpO₂, and Oxygen Deficit, without the pain, risk, or delay of arterial blood gas (ABG) testing. Accurate, objective respiratory data at the patient’s bedside, instantly.
Results in Under 90 Seconds
Speed matters in clinical care. Through a simple tidal breath sampling procedure, the AGM100 provides comprehensive cardiopulmonary diagnostic insights in less than 90 seconds, enabling faster clinical decisions and reducing patient wait times in emergency, ICU, and outpatient settings.
FDA-Cleared, CDSCO-Approved & Clinically Validated
Backed by peer-reviewed clinical publications and recognised by the WHO, the AGM100 is the first FDA-cleared non-invasive gas-exchange monitor of its kind. Clinicians can trust its precision across diverse patient populations and care environments.
Early Detection of Respiratory Conditions
From COPD and asthma to pulmonary fibrosis, ARDS, and post-COVID respiratory impairment, the AGM100 enables early identification of gas exchange abnormalities, empowering timely interventions that improve patient outcomes and reduce disease progression.
Versatile Across All Care Settings
Whether in an emergency room, outpatient clinic, or critical care unit, the AGM100’s portable design and simple breath-sampling process make it deployable wherever patients need cardiorespiratory assessment, without specialised infrastructure.
Reduces Dependence on Invasive & Costly Tests
By providing ABG-comparable results non-invasively, the AGM100 reduces the need for expensive, resource-intensive procedures, making high-quality respiratory diagnostics more accessible, cost-effective, and scalable, especially in resource-constrained healthcare settings.
How Does The AGM100 Work?
Clinical Publications of AGM100
Validation of Noninvasive Assessment of Pulmonary Gas Exchange in Patients with Chronic Obstructive Pulmonary Disease during Initial Exposure to High Altitude
Noninvasive Assessment of Impaired Gas Exchange with the Alveolar Gas Monitor Predicts Clinical Deterioration in COVID-19 Patients
The Alveolar Gas Monitor: An Alternative to Pulse Oximetry for the Noninvasive Assessment of Impaired Gas Exchange in Patients at Risk of Respiratory Deterioration
Translational Physiology for Noninvasive Measurement of Pulmonary Gas Exchange in Patients with Hypoxemic Lung Disease
Measurements of Pulmonary Gas Exchange Efficiency Using Expired Gas and Oximetry: Results in Normal Patients